List view / Grid view
5 November 2014 | By TxCell
TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014...
5 November 2014 | By BerGenBio AS
BerGenBio AS announces that the first patient has been dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway...
CAMO Software, leaders in multivariate data analysis software, and Lonza Group, a leading supplier to the pharma, biotech and specialty ingredients markets, have entered into an agreement where CAMO Software will deliver a PAT software solution for collecting, handling, storing, monitoring and modeling of PAT data. The solution will complement…
5 November 2014 | By Moberg Pharma
Moberg Pharma AB announced that it entered into a services agreement with Emerson Healthcare, a division of Emerson Group, who will provide certain logistical services and all order to cash functions for retailer and wholesaler customers in the U.S...
5 November 2014 | By AOP Orphan
The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market...
5 November 2014 | By The Institute of Cancer Research, London
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said...
5 November 2014 | By myoscience
myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer effective immediately...
4 November 2014 | By Photocure
Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix...
4 November 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...
4 November 2014 | By LEO Pharma and Japan Tobacco
LEO Pharma A/S and Japan Tobacco Inc. announced that the companies have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052...
4 November 2014 | By Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited have announced that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit...
4 November 2014 | By KMR Group
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, has recently assessed the duration of oncology trials...
4 November 2014 | By The European CRO Federation
Patients, healthcare professionals and the public have the right to access clinical research information that may affect patients’ and public health, new and existing treatments of health conditions and access to innovative clinical research...
4 November 2014 | By ABIVAX
ABIVAX has appointed Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively...
4 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in…
